Allertek (mometasone furoate) Nazo nasal spray 50 mcg/dose, 60 doses vial

$16.20

Manufacturer: France

Anti-edematous and other drugs for local use in diseases of the nasal cavity. Corticosteroids. ATX code R01A D09.

  1. Treatment of seasonal or year-round allergic rhinitis in adults and children over 2 years of age. It is recommended to start prophylactic treatment of moderate and severe allergic rhinitis 4 weeks before the expected start of the pollination season.
  2. As an auxiliary therapeutic agent in the treatment with antibiotics of acute episodes of sinusitis in adults (including the elderly) and children over 12 years of age.
  3. Treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children over 12 years of age.
  4. Treatment of nasal polyps and associated symptoms, including nasal congestion and loss of smell, in patients 18 years of age and older.
Category:

Description

Composition

active substance : mometasone furoate;
1 dose contains 50 mcg of mometasone furoate monohydrate (in anhydrous form);
excipients: benzalkonium chloride solution, glycerin, polysorbate-80, microcrystalline cellulose, carmellose sodium, citric acid monohydrate, sodium citrate, water for injections.

Pharmacotherapeutic group

Anti-edematous and other drugs for local use in diseases of the nasal cavity. Corticosteroids. ATX code R01A D09.

Pharmacodynamics

Mometasone furoate is a synthetic corticosteroid for local use, which has a pronounced anti-inflammatory effect. The local anti-inflammatory effect of mometasone furoate occurs in doses that do not cause systemic effects.
Basically, the mechanism of anti-inflammatory and anti-allergic action of mometasone furoate is related to its ability to suppress the release of mediators of allergic reactions. Mometasone furoate significantly reduces the synthesis/release of leukotrienes from leukocytes of patients suffering from allergic diseases. Mometasone furoate demonstrated 10-fold greater activity in cell culture than other steroids including beclomethasone dipropionate, betamethasone, hydrocortisone, and dexamethasone in inhibiting the synthesis/release of IL-1, IL-5, IL-6, and TNFα. It is also a potent inhibitor of Th2 cytokine production, IL-4 and IL-5 from human CD4+ T cells. Mometasone furoate is also 6 times more active than beclomethasone dipropionate and betamethasone in inhibiting IL-5 production.

Indication

  1. Treatment of seasonal or year-round allergic rhinitis in adults and children over 2 years of age. It is recommended to start prophylactic treatment of moderate and severe allergic rhinitis 4 weeks before the expected start of the pollination season.
  2. As an auxiliary therapeutic agent in the treatment with antibiotics of acute episodes of sinusitis in adults (including the elderly) and children over 12 years of age.
  3. Treatment of symptoms of acute rhinosinusitis without signs of severe bacterial infection in adults and children over 12 years of age.
  4. Treatment of nasal polyps and associated symptoms, including nasal congestion and loss of smell, in patients 18 years of age and older.

Contraindication

Hypersensitivity to the active substance or to any inactive component of the drug.

Dosage and Administration

Treatment of seasonal or year-round allergic rhinitis. For adults (including the elderly) and children over 12 years of age, the recommended prophylactic and therapeutic dose of the drug is 2 injections (50 mcg each) into each nostril once a day (total daily dose – 200 mcg). After achieving a therapeutic effect for maintenance therapy, it is advisable to reduce the dose to 1 injection into each nostril once a day (total daily dose – 100 μg).

If alleviation of the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose can be increased to the maximum: 4 injections into each nostril once a day (total daily dose – 400 mcg). After the symptoms of the disease subside, a dose reduction is recommended.

The drug has demonstrated a clinically significant onset of action within 12 hours of first administration in some patients with seasonal allergic rhinitis. However, the full benefit of the treatment cannot be obtained in the first 48 hours, so the patient must continue regular use to achieve the full therapeutic effect.

For children aged 2-11 years, the recommended therapeutic dose is 1 injection (50 mcg) in each nostril 1 time a day (total daily dose – 100 mcg).

Auxiliary treatment of acute episodes of sinusitis. For adults (including the elderly) and children over 12 years of age, the recommended therapeutic dose is 2 injections (50 mcg) in each nostril 2 times a day (total daily dose – 400 mcg).

If alleviation of the symptoms of the disease cannot be achieved by using the drug in the recommended therapeutic dose, the daily dose can be increased to 4 injections in each nostril 2 times a day (total daily dose – 800 mcg). After the symptoms of the disease subside, a dose reduction is recommended.

Acute rhinosinusitis. For adults and children over 12 years of age, the recommended therapeutic dose is 2 injections (50 mcg) in each nostril 2 times a day (total daily dose – 400 mcg).

Nasal polyps. For patients over 18 years of age (including the elderly), the recommended dose is 2 injections (50 mcg) in each nostril 2 times a day (total daily dose – 400 mcg). After achieving a clinical effect, it is recommended to reduce the dose to 2 injections in each nostril once a day (total daily dose – 200 μg).

Application of nasal spray

Before starting to use a new bottle of the drug, it should be calibrated. Calibration is carried out by approximately 10 presses of the dosing device, while establishing a stereotypical delivery of the medicinal substance, in which with each press, approximately 100 mg of suspension containing 50 μg of mometasone (one dose) is released. If the nasal spray has not been used for 14 days or longer, it should be re-sprayed by 2 puffs before the next use until full delivery is observed.

After using the indicated number of doses in the vial or after 2 months from the moment of the first use of the vial, it should be thrown away.

The order of administration of the drug:

  1. Shake the bottle vigorously before each use (Fig. 1).
  2. Before each use, the nose should be thoroughly cleaned of mucus.
  3.  The tip should be placed in the nasal passage, and the other nostril should be closed with a finger, as shown in fig. 2. Tilt your head forward, while holding the bottle vertically.
  4. You should inhale through your nose and press one finger on the nozzle of the bottle.
  5. Exhale through the mouth. Repeat point 4 for a second injection into the same nasal passage.
  6. You should pull out the sprayer from the nasal passage and continue breathing through the mouth.
  7. It is necessary to repeat points 3-6 for the second nostril (Fig. 3).

After using the spray, it is necessary to wipe the spray nozzle of the bottle with a clean napkin and close it with a protective cap.

It is important to regularly clean the dosing device. It is necessary to remove the protective cap and sprayer and wash them with warm running water, dry and install in the previous place. Do not try to clean the nozzle with a needle or other sharp object, as such actions will damage the dispenser.

Regular cleaning of the nozzle is very important.